71 related articles for article (PubMed ID: 24842884)
1. On the road to PARPi-platin.
Bookman MA
J Natl Cancer Inst; 2014 Jun; 106(6):dju119. PubMed ID: 24842884
[No Abstract] [Full Text] [Related]
2. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].
Gorodnova TV; Maksimov SIa; Guseĭnov KD; Imianitov EN
Vopr Onkol; 2014; 60(3):339-42. PubMed ID: 25033687
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; de Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB
Clin Cancer Res; 2013 Oct; 19(19):5485-93. PubMed ID: 23922302
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
[TBL] [Abstract][Full Text] [Related]
5. Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?
Turinetto M; Ray-Coquard I; Gourley C
ESMO Open; 2024 May; 9(5):102983. PubMed ID: 38663167
[No Abstract] [Full Text] [Related]
6. Pancreatic cancer: BRCA mutation and personalized treatment.
Luo G; Lu Y; Jin K; Cheng H; Guo M; Liu Z; Long J; Liu C; Ni Q; Yu X
Expert Rev Anticancer Ther; 2015; 15(10):1223-31. PubMed ID: 26402249
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
Veeck J; Ropero S; Setien F; Gonzalez-Suarez E; Osorio A; Benitez J; Herman JG; Esteller M
J Clin Oncol; 2010 Oct; 28(29):e563-4; author reply e565-6. PubMed ID: 20679605
[No Abstract] [Full Text] [Related]
8. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Moss HA; Perhanidis JA; Havrilesky LJ; Secord AA
Gynecol Oncol; 2021 Oct; 163(1):50-56. PubMed ID: 34301411
[TBL] [Abstract][Full Text] [Related]
9. Rucaparib Approved for Ovarian Cancer.
Cancer Discov; 2017 Feb; 7(2):120-121. PubMed ID: 28057616
[TBL] [Abstract][Full Text] [Related]
10. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
11. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
Tan DS; Yap TA; Hutka M; Roxburgh P; Ang J; Banerjee S; Grzybowska E; Gourley C; Gore ME; Kaye SB
Eur J Cancer; 2013 Apr; 49(6):1246-53. PubMed ID: 23265709
[TBL] [Abstract][Full Text] [Related]
12. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
Kauff ND
J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
[No Abstract] [Full Text] [Related]
13. Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
Ledermann JA
Gynecol Oncol; 2019 May; 153(2):213-214. PubMed ID: 31027611
[No Abstract] [Full Text] [Related]
14. In brief: BRCA1 and BRCA2.
Foulkes WD; Shuen AY
J Pathol; 2013 Aug; 230(4):347-9. PubMed ID: 23620175
[TBL] [Abstract][Full Text] [Related]
15. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
16. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
Ng CK; Cooke SL; Howe K; Newman S; Xian J; Temple J; Batty EM; Pole JC; Langdon SP; Edwards PA; Brenton JD
J Pathol; 2012 Apr; 226(5):703-12. PubMed ID: 22183581
[TBL] [Abstract][Full Text] [Related]
17. [Ovarian cancer].
Langmár Z; Csömör S; Németh M; Tomcsik Z; Joó JG
Orv Hetil; 2011 Dec; 152(49):1977-84. PubMed ID: 22106167
[No Abstract] [Full Text] [Related]
18. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?
Osher DJ; Kushner YB; Arseneau J; Foulkes WD
J Clin Pathol; 2011 Oct; 64(10):924-6. PubMed ID: 21378390
[TBL] [Abstract][Full Text] [Related]
19. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
20. Cancer: crossing over to drug resistance.
Livingston DM; Silver DP
Nature; 2008 Feb; 451(7182):1066-7. PubMed ID: 18305536
[No Abstract] [Full Text] [Related]
[Next] [New Search]
